MBNL1 and leukemia: Similar to our primary transplant experiments, secondary recipients of Mbnl1−/− leukemia cells demonstrated longer leukemia-free survival (65 days) compared to mice secondarily transplanted with Mbnl1+/+ leukemia cells (49 days) (Fig. 3c).